What's in Pedro de Figueiredo Buchalla's pipeline?

Pedro de Figueiredo Buchalla has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Pedro de Figueiredo Buchalla's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/pedro-de-figueiredo-buchalla.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Pedro de Figueiredo Buchalla — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pedro de Figueiredo Buchalla pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Experimental: Alpha-blocker group	Experimental: Alpha-blocker group	marketed	Alpha-blocker	Alpha-1 adrenergic receptor	Cardiovascular; Urology

Therapeutic area mix

Cardiovascular; Urology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Pedro de Figueiredo Buchalla:

Cite this brief

Drug Landscape (2026). Pedro de Figueiredo Buchalla — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pedro-de-figueiredo-buchalla. Accessed 2026-05-16.